The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst
: So just had a multiparter, a very simple one, though. So on sales force, just wondering what the productivity trends were that you're assuming in
the fourth quarter guidance. I guess just like -- just for that context, the 9,000 providers added in the third quarter, then access is still, I guess, 50%
of pre-COVID. And then similar to that, I guess, there's a broad range of companies trying to break into screening or even different cancers, just
obviously the benefit from your sales force and network of provider relationships really helped. So would you ever consider maybe offering a
portion of your sales force on like a temporary contract basis maybe to competitor and whether it's screening or, again, monitoring things like
that?
And finally, I just think this is an important question to kind of ask and to think about, with all these pipeline tests being launched in '23 and '25,
that kind of time frame, there's a lot of long-term potential, obviously, what's going to be the most exciting, I guess, think about Exact between
now and then from an investor perspective?
|
